SUMAWAY drug index by dredwardmark



Name: SUMAWAY, FELICIDAD Age/Sex: 52/M Address: 231 J. Teresa St., Sta. Mesa, Manila Date of admission: March 23, 2008 Admitting Diagnosis: Space Occupying Lesion probably 1. Abscess 2. Malignancy IHD, AF c, MVR, NIF PTB V Residents in charge: Dr. Gutierrez/ Dimaandal/ Areja Clerk-in-Charge: Drs. Florentino/Ingles

Hospital #: 1811972

Drug Cefuroxime

MOA Active against β-lactamaseproducing H. influenzae or K. pneumoniae and penicillinresistant pneumococci Inhibition of protein synthesis by binding to 50s ribosomal subunit

Indication Infections of the respiratory tract, ENT, soft tissues and bones. Also for O and G infections, wound infections, erysipelas and peritonitis. LRTI, URTI, skin and soft tissue infections, mycobacterial infections due to mycobacterium avium or M. intracellulare. Localized infections due to M. chelonei, M. fortuitum, or M. kansasii, Prevention of M. avium complex in HIV patients w/CD4 lyphocyte count equal to or less than 100/mm3. Eradication of H. pylori in the presence of acid suppression, acute otitis media Secondary prevention of cerebrovascular events in patients with transient ischemic attack and minor stroke, reinfarction in patients with previous MI, restenosis of coronary bypass graft, thrombosis of arteriovenous shunts in patients undergoing hemodialysis.


DRUG INDEX CI Hypersensitivity to cephalosporins

DI Concomitant therapy with aminoglycosides may cause renal impairment.

ADR Hypersensitivity reactions, GI disturbances, transient pain at IM injection site

Preparation 250mg vial 750mg vial

Adult: 750mg IM or IV Children: 30100mg/kg/day in 3-4 divided doses.


250 mg or 500 mg BID for 6-14 days

Concomitant use w/ cisapride, pimozide, & terfenadine

Decreased metabolism of cisaspride; possible ventricular arrhythmia; decreased cyclosporine metabolism; reduced renal excretion of digoxin; decreased statin metabolism; decreased pimozide metabolism; decreased theophylline metabolism;

GI disturbances, headache, taste perversion, transient elevation of liver enzymes

Tab 250 mg, 500 mg


Nonselective inhibitor of both COX isoforms

1 tab OB

Severe anemia, blood coagulation defects, renal insufficiency

Activated charcoal, urinary acidifiers, antacids, urinary alkalizers, carbonic anhydrase inhibitor, corticosteroid may affect absorption, excretion or pharmacologic effects of ASA

Nausea, dyspepsia, epigastric discomfort, anorexia, GI bleeding. May worsen peptic ulcer. Hypersensitivity, prolonged bleeding time, leucopenia, thrombocytopenia, purpura, decreased plasma Fe conc, shortened erythrocyte survival time

Tab 80 mg


ACE inhibitor

Hypertension, Heart failure, MI, Diabetic nephropathy

25 mg BID or TID. May inc to 50 mg BID or TID

Hypersensitivity, pregnancy


Inhibits stimulation of β1adrenoreceptors such as those in the heart but 50 to 100 fold less potent than propanolol in blocking β2receptors

Hypertension, chronic angina pectoris

50 mg BID or 100mg OD


Denitration of the drug, with release of free nitrite iion, relaxes cardiac smooth muscle cels. Β2 Selective adrenoceptor agonist

Salbutamol + Ipathropium or PNSS nebulization

Piperacillin + Tazobactam

Tazobactam potent inhibitors of bacterial βlactamases, inhibits chromosomal βlactamases of bacteroides and branhamella, staphylococcus, H influenzae, N gonorrhea, salmonella, shigella, E coli, and K pneumoniae, tazobactams can protect hydrolysis of penicillins from inactivation by bacteria β lactamases

CHD, angina pectoris, MI, CHF, chronic right ventricular failure, chronic cor pulmonale, acute left ventricular failure Prevention and/or relief of bronchospasm, associated w/reversible obstructive airway disease, eg, bronchial asthma, & treatment of exacerbations of asthma Treatment of systemic &/or local bacterial infections caused by susceptible organisms; UTI, lower respiratory tract, intraabdominal; skin & skin structure infections; bone and joint; gynecologic; bacterial infections in neutropenic patients; bacterial septicemia; polymicrobic infections.

Angina attack: 1 tab SL 2-3 hourly

Heart block greater than 1st degree AV blocks II & III, cardiogenic shock, overt cardiac failure, sinus bradycardia, greater than first degree AV blocks II & III, cardiogenic shock, overt cardiac failure, sinus bradycardia, 1st trimester of pregnancy Very low BP, acute MI w/ low filling pressure except in ICU, shoch w/ vascular collapse

Patients on prior diuretics, nitrated, K-sparing diuretics, NSAID’s, Indomethacin, lithium Sympathomimetics

Rash, dysgeusia, taste alteration, neutropenia, cough

Tab 25 mg, 50 mg

GI and sleep pattern disturbances, headaches, dizziness, weakness

Tab 50 mg, 100 mg

Alcohol, antihypertensives, Beta blockers, phenothiazines

Cutaneous vasodilatation w/ nausea, vomiting

Tab 5 mg, 10 mg; SL tab 5 mg

2.5 to 5 mg TID-QID

MAOIs, TCADs, βblocker

Palpitations, tachycardia, increased BP, headache, nervousness, dizziness, bronchospasms, cough, bronchitis

Pulmoneb 2.5 mg/2.5 ml

Total daily dose 2.25-4.5 g administered 6 or 8 hourly by slow IV inj (≥3-5 min) or IV infusion (20-30 min).

Hypersensitivity to penicillins, cephalospirins, or β-lactamase inhibitors.

Probenecid, vecuronium, drugs affecting blood coagulation, &/or thrombocyte function, methotrexate

Diarrhea, nausea, vomiting, rash, leucopenia, neutropenia, thrombocytopenia, hypersensitivity reaction, headache, insomnia, hypotension, phlebitis, thrombophlebitis, constipation, dyspepsia, jaundice, stomatitis, increased blood creatinine, pruritus, urticaria, fever, inj site reaction

Vial 2.25 g

To top